<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03027635</url>
  </required_header>
  <id_info>
    <org_study_id>PETRA21042016</org_study_id>
    <nct_id>NCT03027635</nct_id>
  </id_info>
  <brief_title>PEriToneal Catheter Versus Repeated Paracentesis for Ascites in Cirrhosis</brief_title>
  <acronym>PETRA</acronym>
  <official_title>Tunnelated Peritoneal Catheter Versus Repeated Large Volume Paracentesis for Diuretic Resistant Ascites in Patients With Cirrhosis: An Investigator Initiated, Open, Parallel Arm Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nina Kimer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Copenhagen University Hospital, Hvidovre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insertion of a tunnelated peritoneal catheter (PleurX) allows repeated intermittent small
      volume fluid drainage at home. The treatment may improve the management of ascites and have a
      beneficial effect on the quality of life.

      This study aims to evaluate the beneficial and harmful effects of the peritoneal catheter
      (PleurX) versus repeated large volume paracentesis for patients with cirrhosis and diuretic
      resistant ascites.

      The trial is an investigator initiated, randomised, single blind, parallel arm, controlled
      trial.

      Tunnelated peritoneal (PleurX) catheter versus large volume paracentesis. All patients will
      receive ciprofloxacin to prevent spontaneous bacterial peritonitis.

      We will include 32 adult patients with cirrhosis Duration of trial 18 months. The total
      duration of follow up is six months. The primary outcome is paracentesis free survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ten percent of patients with cirrhosis develop ascites. In 90% of patients, ascites can be
      treated with diuretics. The management of the remaining 10% with diuretic resistant ascites
      is challenging. Symptoms including abdominal pain, dyspnoea, nausea, vomiting, and anorexia
      have a detrimental impact on the quality of life. Repeated large volume paracentesis provides
      only temporary improvement of symptoms.

      Insertion of a tunnelated peritoneal catheter (PleurX) allows repeated intermittent small
      volume fluid drainage at home. The treatment may improve the management of ascites and have a
      beneficial effect on the quality of life.

      To evaluate the beneficial and harmful effects of the peritoneal catheter (PleurX) versus
      repeated large volume paracentesis for patients with cirrhosis and diuretic resistant
      ascites.

      Investigator initiated, randomised, single blind, parallel arm, controlled trial.

      Due to the nature of the intervention and the primary outcome measure, Investigators are
      unable to conduct the trial with blinding of the patients, the investigators or use blinded
      outcome assessment.

      Tunnelated peritoneal (PleurX) catheter versus large volume paracentesis. All patients will
      receive ciprofloxacin to prevent spontaneous bacterial peritonitis.

      The study investigators will include 32 adult patients with cirrhosis of any aetiology and
      diuretic resistant ascites.

      Gastrounit, Hvidovre University Hospital, Department of Gastroenterology and Hepatology,
      Odense University Hospital, Department of Gastroenterology and Hepatology, Aarhus University
      Hospital, and Centre for Hepatology, UCL Institute for Liver and Digestive Health, Royal Free
      Campus, University College London, UK 18 months. The total duration of follow up is six
      months. The primary outcome is paracentesis free survival. Secondary outcomes include
      cumulative number of paracentesis, cirrhosis-related complications, safety, quality of life,
      changes in metabolic and nutritional parameters, circulatory dysfunction, renal function,
      cardiac output, neuro-humoral changes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first paracentesis</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>18 months</time_frame>
    <description>Number of AEs in groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional Status</measure>
    <time_frame>18 months</time_frame>
    <description>Indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>18 months</time_frame>
    <description>glomerular filtration rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>18 months</time_frame>
    <description>cardiac output</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Ascites Hepatic</condition>
  <condition>Ascites (Non-Malignant)</condition>
  <arm_group>
    <arm_group_label>PleurX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The PleurX catheter is a tunnelated peritoneal catheter, designed for permanent placement in the peritoneal cavity. The catheter is placed by a physician under sterile conditions. Drainage of ascites is done using vacuum bottles connected to the catheter. This can be managed by a home nurse or the patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Large Volume Paracentesis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Large volume paracentesis is performed in sterile technique, a small incision is made through the skin, and a catheter is inserted through muscle and peritoneum. After the procedure, the patient remains in hospital for observation until the fluid is drained.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PleurX, peritoneal tunnelated catheter</intervention_name>
    <description>A permanent catheter</description>
    <arm_group_label>PleurX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Large Volume Paracentesis</intervention_name>
    <description>Short time drainage</description>
    <arm_group_label>Large Volume Paracentesis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin 500Mg Tablet</intervention_name>
    <description>SBP prophylaxis</description>
    <arm_group_label>PleurX</arm_group_label>
    <arm_group_label>Large Volume Paracentesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cirrhosis of any aetiology

          -  Diuretic resistant ascites defined as i) an inability to mobilise ascites (minimal or
             no weight loss) despite administration with the maximum tolerable doses of oral
             diuretics or a daily dose of spironolactone 400 mg and re-accumulation of fluid after
             therapeutic paracentesis within two weeks or ii) diuretic-related complications
             including (but not limited to) azotemia, hepatic encephalopathy, or progressive
             electrolyte imbalances

          -  Able to read and understand Danish

          -  Signed and dated informed consent form

          -  Willing to comply with all study procedures and be available for the duration of the
             study

          -  Male or female of any age

          -  Age at least 18 years

          -  Expected survival at least three months.

        Exclusion Criteria:

          -  Participants eligible and listed for TIPS

          -  Serum creatinine levels above 135 umol/L

          -  Overt hepatic encephalopathy in the two weeks before randomization

          -  Ascites due to other causes than cirrhosis such as: malignant disease, congestive
             heart failure, end-stage renal disease, pancreatitis, or Budd-Chiari (hepatic vein
             thrombosis), or chylous ascites

          -  Ongoing intra-abdominal infection (peritonitis) or active systemic or local
             infections, such as urinary tract infection or pneumonia

          -  Participation in a clinical study that may interfere with participation in this study;

          -  Evidence of extensive ascites loculation

          -  Coagulopathy

          -  Variceal bleeding within two weeks before randomisation

          -  Intraabdominal surgery within four months before randomisation

          -  Spontaneous bacterial peritonitis (neutrophil count&gt;250/Âµl within 24 hours of
             randomization)

          -  Patients with an increased risk of procedure related complications as judged by the
             primary healthcare provider
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nina Kimer, MD, PhD</last_name>
    <phone>+45 38623862</phone>
    <email>nina.kimer@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lise Lotte Gluud, MD, DmSC</last_name>
    <phone>+45 39621962</phone>
    <email>lise.lotte.gluud.01@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gastro Unit, medical Division, University Hospital Hvidovre</name>
      <address>
        <city>Hvidovre</city>
        <state>Danmark</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Kimer, PhD</last_name>
      <email>nina.kimer@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2016</study_first_submitted>
  <study_first_submitted_qc>January 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2017</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Copenhagen University Hospital, Hvidovre</investigator_affiliation>
    <investigator_full_name>Nina Kimer</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>diuretic resistant ascites</keyword>
  <keyword>Paracentesis</keyword>
  <keyword>PleurX</keyword>
  <keyword>Peritoneal tunnelated catheter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Due to Danish Legislation only anonymized data may be available upon request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

